Dose Evaluation and Optimization of Amoxicillin in Children Treated for Lyme Disease
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.6190 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Anne Ravix und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerlan…. Hauptthemen laut MEDLINE: Amoxicillin, Lyme Disease, Anti-Bacterial Agents, Models, Biological. Die Arbeit nennt 64 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Amoxicillin is commonly used to treat erythema migrans in the first stage of Lyme disease in children, with a recommended dose of 50 mg/kg/day, administered three times a day (q8h). This model‐based simulation study aimed to determine whether splitting the same daily dose into two administrations (q12h) would provide comparable drug exposure. A pharmacokinetic model suitable for a pediatric population (age: 1 month to 18 years, weight: 4‐80 kg) was selected through a literature review. Simulations were performed with 15,000 virtual patients receiving 16.67 mg/kg/dose q8h, 25 mg/kg/dose q12h, or other q12h dosing variations. The target therapeutic level was defined by the percentage of time that the unbound drug concentration remained above the minimum inhibitory concentration (% fT > MIC) specific to Borrelia burgdorferi , with MICs of 0.06, 0.25, 1, 2, and 4 mg/L, requiring at least 40% and 50% of time for effective treatment. Probability of target attainment (PTA) was considered acceptable if it exceeded 50%, allowing for comparison of dosing schedules. Results indicated that the 50 mg/kg/day divided q12h regimen provided similar drug exposure to the q8h regimen for MICs below 2 mg/L (PTAs >50%). For a MIC of 2 mg/L, PTA was achieved with a higher dose of 30 mg/kg/dose q12h. However, for a MIC of 4 mg/L, the PTA criterion was not met. These findings suggest that a twice‐daily dosing of 25 mg/kg/dose provides comparable bactericidal activity to the thrice‐daily regimen for MICs between 0.06 and 1 mg/L. This simplified regimen may improve adherence and treatment implementation in children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Division of Pediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel, Switzerland.
- SwissPedDose/SwissPedNet Collaboration Expert Team, Zurich, Switzerland.
- Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Zurich, Switzerland.
- SwissPedDose, Zürich, Switzerland.
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
ORCID-Profile: Verena Gotta, Marc Pfister, Monia Guidi
Zitieren
APA
Ravix, A., Gotta, V., Pfister, M., Berger, C., Glauser, A., Paioni, P., Csajka, C., & Guidi, M. (2025). Dose Evaluation and Optimization of Amoxicillin in Children Treated for Lyme Disease. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6190
Vancouver
Ravix A, Gotta V, Pfister M, Berger C, Glauser A, Paioni P, et al. Dose Evaluation and Optimization of Amoxicillin in Children Treated for Lyme Disease. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.6190
BibTeX
@article{Ravix2025,
author = {Ravix, Anne and Gotta, Verena and Pfister, Marc and Berger, Christoph and Glauser, Antonia and Paioni, Paolo and Csajka, Chantal and Guidi, Monia},
title = {Dose Evaluation and Optimization of Amoxicillin in Children Treated for Lyme Disease},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.6190}
}
EUVIMED